SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after reporting substantial year-over-year revenue growth and expanded global approvals for its ANKTIVA cancer therapies in new markets and indications like lung cancer. The community is buzzing with talk of a potential short squeeze, encouraging buying dips, and anticipating significant long-term upside as the company broadens its global commercial footprint.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to its FDA approval of BYSANTI for bipolar I disorder and schizophrenia, a pivotal development underscored by its New Chemical Entity (NCE) status and patent protection until 2044. The community anticipates a significant re-rating and potential short squeeze, highlighting that this second recent FDA approval makes the company vastly undervalued compared to prior rejected buyout offers.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing a significant downturn after its CagriSema weight-loss drug demonstrated slightly lower efficacy than a competitor in a recent trial, prompting community discussion on whether the market's reaction is an overcorrection despite NVO's strong financial position and other successful products.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after releasing positive Phase 2 trial data for its lead drug sonelokimab in axial spondyloarthritis, showing high efficacy and signs of disease modification ahead of its Investor Day. The community views this, coupled with a strong cash position and high short interest, as a significant re-rating catalyst, anticipating a substantial surge and potential for best-in-class market positioning.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending due to a sector-wide sell-off following Anthropic's Claude Code Security announcement, with community members divided on whether AI threatens CRWD's core endpoint and cloud security or reinforces the need for its advanced, AI-native platform.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as a top contender in the obesity drug market after a competitor's recent trial results underscored the potential superiority and tolerability of Viking's dual GLP-1/GIP agonist, VK2735. The community is actively discussing massive short interest, the advancing oral program, and intense speculation about an imminent buyout or significant partnership with a major pharmaceutical company seeking a leading position in the rapidly expanding metabolic space.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx Inc. is trending sharply higher after Gilead Sciences announced a definitive agreement to acquire the company for $7.8 billion, including a substantial premium per share. The community is actively discussing this major buyout as a validation of Arcellx's promising CAR T therapy, anito-cel for multiple myeloma, and a significant event that highlights acquisition potential within the biotech sector.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna (MRNA) is trending after the FDA reversed its initial refusal and agreed to review the company's seasonal flu vaccine application, igniting a significant short squeeze and renewed optimism for its broader mRNA pipeline, particularly in oncology and other respiratory diseases.

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

20/20 Biolabs Inc

Recent IPO AIDX is trending due to extreme volatility and significant community debate, with some labeling it a 'pump and dump' anticipating further declines while others expect a major bounce, all within a broader sector experiencing pressure.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is trending after its latest earnings revealed increased U.S. market share and continued international same-store sales growth, alongside a significant dividend hike, signaling strong operational execution. The community is discussing these results and an increased stake by notable investors as key drivers, highlighting the company's "Hungry for MORE" strategy and resilience in the restaurant sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dollar at a 4-Year Low? ETFs That You Could Play

The U.S. dollar sinks to a four-year low as rate-cut bets and policy uncertainty rise. These ETFs offer investors a way to hedge, diversify and capitalize on opportunities

ETFs That Investors May Consider Amid a Dollar Drag

As the dollar weakens and rate-cut bets rise, these ETFs offer investors a way to hedge, diversify and capitalize on opportunities.

What's Driving Precious Metal ETFs Rally in 2025?

Precious metal ETFs like GLTR, PPLT, GLD and SLV shine in 2025, lifted by safe-haven demand, strong industrial consumption and tight supply.


The GLTR ETF May Be a ‘Golden’ Opportunity Now

I use Barchart’s screening functions to find stocks with high technical “buy” signals and strong momentum, but this method struggles in the current market. Despite declines in the S&amp;P 500 Index ($SPX) and Nasdaq-100 Index ($IUXX) , precious metals like gold and silver are performing well.  This makes the Aberdeen...

Precious Metals in Q1 2025- Where are they Heading in Q2?

The precious metals sector led the commodities asset class higher in Q1 2025, with over 18% gains in gold and silver. Platinum and palladium prices moved to the upside, and rhodium posted an over 20% gain in the quarter that ended on March 31, 2025.

Precious Metals in Q4 and 2024- Where are they Heading in 2025?

The precious metals sector declined in Q4 but moved to the upside in 2024. While gold and silver posted over 20% gains for the year, platinum and palladium futures were down over 10%. Gold was the only precious metal moving higher in Q4, as the price rose to a new record peak during the year’s final quarter.

Current Price	$241.64
Prev Close	$232.37
Open	$236.14
Dividend Yield	N/A
50-Day Moving Average	$226.80
Beta	N/A
Avg. Volume	274,621.05
PE Ratio	N/A

52-Week High	$295.44
52-Week Low	$117.50
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

GLTR
abrdn ETF - abrdn Physical Precious Metals Basket Shares ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GLTR News

GLTRabrdn ETF - abrdn Physical Precious Metals Basket Shares ETF